Skip to Main Content
DownloadHi-Res Photo

Harriet Kluger, MD

Professor of Medicine (Medical Oncology); Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Director, Yale Immuno-Oncology Training Program; Harvey and Katherine Cushing Professor, Internal Medicine; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

Contact Information

Harriet Kluger, MD

Mailing Address

  • Medical Oncology

    PO Box 208032

    New Haven, CT 06520-8028

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Kluger is a medical oncologist and the Associate Director for Education, Training and Faculty Development at Yale Cancer Center, and the Deputy Section Chief for Medical Oncology. She sees patients with melanoma and renal cell carcinoma. Approximately half of her time is spent conducting laboratory-based clinical and translational research. She runs an active laboratory focusing on melanoma-related studies, and has been an integral member of the Yale SPORE in Skin Cancer since it was initially awarded in 2006, having co-led four projects during this time. She is currently a Director of the SPORE in Skin Cancer with Dr. Bosenberg. Dr. Kluger collaborates with basic and clinical scientists to develop new approaches for the diseases she treats, including new approaches for patients with brain metastases. Her particular focus is on predictive biomarkers and development of novel therapies, primarily immune activating approaches. She has extensive experience in conducting correlative predictive and prognostic biomarker studies using a variety of technologies, including exome sequencing, expression arrays, tissue microarrays, single cell technologies and others. Her lab conducts pre-clinical targeted drug testing and knock-down studies. She also has experience in designing and conducting clinical trials with laboratory correlates, including investigator initiated trials. All of these trials involve specimen collection (tumor and blood) and analysis. She has been very involved in development of single drug and combination checkpoint regimens, and is well versed with aspects of biomarker development for predicting response to this class of drugs.

Coauthors

Research Interests

Medical Oncology; Melanoma

Selected Publications

  • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. The Lancet. Oncology 2016, 17: 976-983. PMID: 27267608, PMCID: PMC5526047, DOI: 10.1016/S1470-2045(16)30053-5.
  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. The New England Journal Of Medicine 2016, 374: 2542-52. PMID: 27093365, PMCID: PMC4927341, DOI: 10.1056/NEJMoa1603702.
  • Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 2016, 122: 3051-8. PMID: 27285122, PMCID: PMC5030143, DOI: 10.1002/cncr.30138.
  • Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL, Kluger HM. Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunology Research 2016, 4: 179-82. PMID: 26701266, PMCID: PMC4881844, DOI: 10.1158/2326-6066.CIR-15-0160.
  • Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism.Hollander L, Guo X, Velazquez H, Chang J, Safirstein R, Kluger HM, Cha C, Desir G. Renalase Expression by Melanoma and Tumor-Associated Macrophages Promotes Tumor Growth through a STAT3-Mediated Mechanism. Cancer Research 2016, 76: 3884-94. PMID: 27197188, PMCID: PMC5031238, DOI: 10.1158/0008-5472.CAN-15-1524.
  • Melanoma central nervous system metastases: current approaches, challenges, and opportunities.Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell & Melanoma Research 2016, 29: 627-642. PMID: 27615400, PMCID: PMC5398760, DOI: 10.1111/pcmr.12538.
  • Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. British Journal Of Cancer 2017, 116: 432-440. PMID: 28103611, PMCID: PMC5318966, DOI: 10.1038/bjc.2016.419.
  • PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.Kluger HM, Zito CR, Turcu G, Baine M, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2017, 23: 4270-4279. PMID: 28223273, PMCID: PMC5540774, DOI: 10.1158/1078-0432.CCR-16-3146.
  • Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research 2003, 63: 8103-7. PMID: 14678960.
  • Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Research 2004, 64: 5270-82. PMID: 15289333, DOI: 10.1158/0008-5472.CAN-04-0731.
  • Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study.Kluger HM, DiVito K, Berger AJ, Halaban R, Ariyan S, Camp RL, Rimm DL. Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Research 2004, 14: 207-10. PMID: 15179190, DOI: 10.1097/01.cmr.0000130874.33504.2f.
  • Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome.Berger AJ, Camp RL, Divito KA, Kluger HM, Halaban R, Rimm DL. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Research 2004, 64: 8767-72. PMID: 15574789, DOI: 10.1158/0008-5472.CAN-04-1384.
  • Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis.Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2004, 10: 173-7. PMID: 14734466, DOI: 10.1158/1078-0432.ccr-0699-3.
  • alphaB-crystallin as a marker of lymph node involvement in breast carcinoma.Chelouche-Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE. alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 2004, 100: 2543-8. PMID: 15197794, DOI: 10.1002/cncr.20304.
  • Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Research 2004, 64: 8773-7. PMID: 15574790, DOI: 10.1158/0008-5472.CAN-04-1387.
  • cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model.Kluger HM, Kluger Y, Gilmore-Hebert M, DiVito K, Chang JT, Rodov S, Mironenko O, Kacinski BM, Perkins AS, Sapi E. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Laboratory Investigation; A Journal Of Technical Methods And Pathology 2004, 84: 320-31. PMID: 14767486, DOI: 10.1038/labinvest.3700044.
  • Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2005, 11: 4083-9. PMID: 15930343, DOI: 10.1158/1078-0432.CCR-04-2191.
  • Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.Kluger HM, Chelouche Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm DL, Price JE. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Research 2005, 65: 5578-87. PMID: 15994930, DOI: 10.1158/0008-5472.CAN-05-0108.
  • Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2005, 11: 5188-94. PMID: 16033835, DOI: 10.1158/1078-0432.CCR-05-0158.
  • Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2006, 12: 3856-63. PMID: 16778114, PMCID: PMC1839847, DOI: 10.1158/1078-0432.CCR-06-0190.
  • Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.Noronha V, Cooper DL, Higgins SA, Murren JR, Kluger HM. Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. The Lancet. Oncology 2006, 7: 270-1. PMID: 16510337, DOI: 10.1016/S1470-2045(06)70619-2.
  • Rab33A: characterization, expression, and suppression by epigenetic modification.Cheng E, Trombetta SE, Kovacs D, Beech RD, Ariyan S, Reyes-Mugica M, McNiff JM, Narayan D, Kluger HM, Picardo M, Halaban R. Rab33A: characterization, expression, and suppression by epigenetic modification. The Journal Of Investigative Dermatology 2006, 126: 2257-71. PMID: 16810302, DOI: 10.1038/sj.jid.5700386.
  • Characterizing disease states from topological properties of transcriptional regulatory networks.Tuck DP, Kluger HM, Kluger Y. Characterizing disease states from topological properties of transcriptional regulatory networks. BMC Bioinformatics 2006, 7: 236. PMID: 16670008, PMCID: PMC1482723, DOI: 10.1186/1471-2105-7-236.
  • Association between pathways in regulatory networks.Kluger Y, Kluger H, Tuck D. Association between pathways in regulatory networks. Conference Proceedings : ... Annual International Conference Of The IEEE Engineering In Medicine And Biology Society. IEEE Engineering In Medicine And Biology Society. Annual Conference 2006, 2006: 2036-40. PMID: 17946929, DOI: 10.1109/IEMBS.2006.260730.
  • The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. Journal Of Translational Medicine 2007, 5: 6. PMID: 17257402, PMCID: PMC1796544, DOI: 10.1186/1479-5876-5-6.
  • High HSP90 expression is associated with decreased survival in breast cancer.Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Research 2007, 67: 2932-7. PMID: 17409397, DOI: 10.1158/0008-5472.CAN-06-4511.
  • Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer.Bromberg KD, Kluger HM, Delaunay A, Abbas S, DiVito KA, Krajewski S, Ronai Z. Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. Cancer Research 2007, 67: 8172-9. PMID: 17804730, PMCID: PMC2962863, DOI: 10.1158/0008-5472.CAN-07-0045.
  • Suppressor role of activating transcription factor 2 (ATF2) in skin cancer.Bhoumik A, Fichtman B, Derossi C, Breitwieser W, Kluger HM, Davis S, Subtil A, Meltzer P, Krajewski S, Jones N, Ronai Z. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 1674-9. PMID: 18227516, PMCID: PMC2234203, DOI: 10.1073/pnas.0706057105.
  • Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells.Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, Camp RL. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Laboratory Investigation; A Journal Of Technical Methods And Pathology 2008, 88: 962-72. PMID: 18626467, DOI: 10.1038/labinvest.2008.65.
  • Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Research : BCR 2008, 10: R35. PMID: 18430249, PMCID: PMC2397537, DOI: 10.1186/bcr1998.
  • Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2008, 14: 4455-62. PMID: 18628459, PMCID: PMC5849429, DOI: 10.1158/1078-0432.CCR-07-5268.
  • Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. Journal Of Immunotherapy (Hagerstown, Md. : 1997) 2008, 31: 569-76. PMID: 18528297, DOI: 10.1097/CJI.0b013e318177a4ba.
  • Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2008, 21: 1121-9. PMID: 18552823, PMCID: PMC2570478, DOI: 10.1038/modpathol.2008.100.
  • HSP90 as a marker of progression in melanoma.McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, Rimm DL, Kluger HM. HSP90 as a marker of progression in melanoma. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2008, 19: 590-4. PMID: 18037622, DOI: 10.1093/annonc/mdm545.
  • Apoptosis: a clinical perspective.Borden EC, Kluger H, Crowley J. Apoptosis: a clinical perspective. Nature Reviews. Drug Discovery 2008, 7: 959. PMID: 19065702, DOI: 10.1038/nrd2756.
  • Assessing expression of apoptotic markers using large cohort tissue microarrays.Pick E, McCarthy MM, Kluger HM. Assessing expression of apoptotic markers using large cohort tissue microarrays. Methods In Molecular Biology (Clifton, N.J.) 2008, 414: 83-93. PMID: 18175814, DOI: 10.1007/978-1-59745-339-4_8.
  • C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2009, 15: 5704-13. PMID: 19737955, PMCID: PMC2763114, DOI: 10.1158/1078-0432.CCR-09-0198.
  • Melanoma prognostic model using tissue microarrays and genetic algorithms.Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL. Melanoma prognostic model using tissue microarrays and genetic algorithms. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2009, 27: 5772-80. PMID: 19884546, PMCID: PMC2792999, DOI: 10.1200/JCO.2009.22.8239.
  • Chemotherapy and biologic therapies for melanoma: do they work?Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clinics In Dermatology 2009, 27: 614-25. PMID: 19880049, DOI: 10.1016/j.clindermatol.2008.09.020.
  • Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2009, 15: 1076-85. PMID: 19188183, PMCID: PMC4263281, DOI: 10.1158/1078-0432.CCR-08-2280.
  • Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2009, 15: 3029-36. PMID: 19383818, PMCID: PMC4431617, DOI: 10.1158/1078-0432.CCR-08-2768.
  • Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer.Woo HH, Zhou Y, Yi X, David CL, Zheng W, Gilmore-Hebert M, Kluger HM, Ulukus EC, Baker T, Stoffer JB, Chambers SK. Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer. Oncogene 2009, 28: 1176-86. PMID: 19151756, DOI: 10.1038/onc.2008.469.
  • Centrosomal Chk2 in DNA damage responses and cell cycle progression.Golan A, Pick E, Tsvetkov L, Nadler Y, Kluger H, Stern DF. Centrosomal Chk2 in DNA damage responses and cell cycle progression. Cell Cycle (Georgetown, Tex.) 2010, 9: 2647-56. PMID: 20581449, PMCID: PMC3233491, DOI: 10.4161/cc.9.13.12121.
  • A role for ATF2 in regulating MITF and melanoma development.Shah M, Bhoumik A, Goel V, Dewing A, Breitwieser W, Kluger H, Krajewski S, Krajewska M, Dehart J, Lau E, Kallenberg DM, Jeong H, Eroshkin A, Bennett DC, Chin L, Bosenberg M, Jones N, Ronai ZA. A role for ATF2 in regulating MITF and melanoma development. PLoS Genetics 2010, 6: e1001258. PMID: 21203491, PMCID: PMC3009656, DOI: 10.1371/journal.pgen.1001258.
  • Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2010, 16: 6029-39. PMID: 21169255, PMCID: PMC3058635, DOI: 10.1158/1078-0432.CCR-10-1490.
  • Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.Parisi F, Gonzalez AM, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Research : BCR 2010, 12: R66. PMID: 20809974, PMCID: PMC3096952, DOI: 10.1186/bcr2633.
  • Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Human Pathology 2010, 41: 375-84. PMID: 20004943, PMCID: PMC2824079, DOI: 10.1016/j.humpath.2009.08.016.
  • Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. Journal Of Translational Medicine 2010, 8: 67. PMID: 20630094, PMCID: PMC2917408, DOI: 10.1186/1479-5876-8-67.
  • Ipilimumab: a promising immunotherapy for melanoma.Thumar JR, Kluger HM. Ipilimumab: a promising immunotherapy for melanoma. Oncology (Williston Park, N.Y.) 2010, 24: 1280-8. PMID: 21294471.
  • Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.Nadler Y, González AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2010, 21: 466-473. PMID: 19717535, PMCID: PMC2826097, DOI: 10.1093/annonc/mdp346.
  • In vitro studies of dasatinib, its targets and predictors of sensitivity.Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell & Melanoma Research 2011, 24: 386-9. PMID: 21320292, PMCID: PMC4431976, DOI: 10.1111/j.1755-148X.2011.00835.x.
  • A phase 2 trial of dasatinib in advanced melanoma.Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011, 117: 2202-8. PMID: 21523734, PMCID: PMC3116034, DOI: 10.1002/cncr.25766.
  • Plasma markers for identifying patients with metastatic melanoma.Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R. Plasma markers for identifying patients with metastatic melanoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2011, 17: 2417-25. PMID: 21487066, PMCID: PMC3415234, DOI: 10.1158/1078-0432.CCR-10-2402.
  • Molecular alternations in uveal melanoma.Materin MA, Faries M, Kluger HM. Molecular alternations in uveal melanoma. Current Problems In Cancer 2011, 35: 211-24. PMID: 21911184, DOI: 10.1016/j.currproblcancer.2011.07.004.
  • Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. Journal Of Translational Medicine 2011, 9: 133. PMID: 21834980, PMCID: PMC3173341, DOI: 10.1186/1479-5876-9-133.
  • USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains.Scortegagna M, Subtil T, Qi J, Kim H, Zhao W, Gu W, Kluger H, Ronai ZA. USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains. The Journal Of Biological Chemistry 2011, 286: 27333-41. PMID: 21659512, PMCID: PMC3149327, DOI: 10.1074/jbc.M111.218214.
  • Melanoma brain metastases: is it time to reassess the bias?Flanigan JC, Jilaveanu LB, Faries M, Sznol M, Ariyan S, Yu JB, Knisely JP, Chiang VL, Kluger HM. Melanoma brain metastases: is it time to reassess the bias? Current Problems In Cancer 2011, 35: 200-10. PMID: 21911183, PMCID: PMC3173717, DOI: 10.1016/j.currproblcancer.2011.07.003.
  • Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.Burke MM, Kluger HM, Golden M, Heller KN, Hoos A, Sznol M. Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29: e792-4. PMID: 21990407, DOI: 10.1200/JCO.2011.36.9199.
  • Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PloS One 2012, 7: e31331. PMID: 22355357, PMCID: PMC3280285, DOI: 10.1371/journal.pone.0031331.
  • Integrated analysis of tumor samples sheds light on tumor heterogeneity.Parisi F, Micsinai M, Strino F, Ariyan S, Narayan D, Bacchiocchi A, Cheng E, Xu F, Li P, Kluger H, Halaban R, Kluger Y. Integrated analysis of tumor samples sheds light on tumor heterogeneity. The Yale Journal Of Biology And Medicine 2012, 85: 347-61. PMID: 23012583, PMCID: PMC3447199.
  • Immunotherapy for metastatic melanoma.Zito CR, Kluger HM. Immunotherapy for metastatic melanoma. Journal Of Cellular Biochemistry 2012, 113: 725-34. PMID: 22006439, DOI: 10.1002/jcb.23402.
  • Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. Journal Of Neurosurgery 2012, 117: 227-33. PMID: 22702482, PMCID: PMC6098938, DOI: 10.3171/2012.5.JNS111929.
  • Vertical pathway targeting in cancer therapy.Shahbazian D, Sznol J, Kluger HM. Vertical pathway targeting in cancer therapy. Advances In Pharmacology (San Diego, Calif.) 2012, 65: 1-26. PMID: 22959021, DOI: 10.1016/B978-0-12-397927-8.00001-4.
  • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics 2012, 44: 1006-14. PMID: 22842228, PMCID: PMC3432702, DOI: 10.1038/ng.2359.
  • Driver mutations in melanoma: lessons learned from bench-to-bedside studies.Mehnert JM, Kluger HM. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Current Oncology Reports 2012, 14: 449-57. PMID: 22723080, PMCID: PMC4447200, DOI: 10.1007/s11912-012-0249-5.
  • CD70 expression patterns in renal cell carcinoma.Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL. CD70 expression patterns in renal cell carcinoma. Human Pathology 2012, 43: 1394-9. PMID: 22401771, PMCID: PMC3374042, DOI: 10.1016/j.humpath.2011.10.014.
  • Drug targets and predictive biomarkers in the management of metastatic melanoma.Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics And Personalized Medicine 2012, 5: 139-48. PMID: 23226069, PMCID: PMC3513235, DOI: 10.2147/PGPM.S25100.
  • PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria.Lau E, Kluger H, Varsano T, Lee K, Scheffler I, Rimm DL, Ideker T, Ronai ZA. PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell 2012, 148: 543-55. PMID: 22304920, PMCID: PMC3615433, DOI: 10.1016/j.cell.2012.01.016.
  • Vascularity of primary and metastatic renal cell carcinoma specimens.Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens. Journal Of Translational Medicine 2013, 11: 15. PMID: 23316728, PMCID: PMC3561185, DOI: 10.1186/1479-5876-11-15.
  • Ipilimumab-induced perforating colitis.Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced perforating colitis. Journal Of Clinical Gastroenterology 2013, 47: 781-5. PMID: 23632354, PMCID: PMC6091636, DOI: 10.1097/MCG.0b013e31828f1d51.
  • Nivolumab plus ipilimumab in advanced melanoma.Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. The New England Journal Of Medicine 2013, 369: 122-33. PMID: 23724867, PMCID: PMC5698004, DOI: 10.1056/NEJMoa1302369.
  • Radiation sensitivity and sensitization in melanoma.Shahbazian D, Bindra RS, Kluger HM, Glazer PM. Radiation sensitivity and sensitization in melanoma. Pigment Cell & Melanoma Research 2013, 26: 928-30. PMID: 23870422, PMCID: PMC3866027, DOI: 10.1111/pcmr.12147.
  • Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.Jilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM. Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PloS One 2013, 8: e69748. PMID: 23936348, PMCID: PMC3735539, DOI: 10.1371/journal.pone.0069748.
  • Advances in the systemic treatment of metastatic melanoma.Yushak M, Kluger HM, Sznol M. Advances in the systemic treatment of metastatic melanoma. Oncology (Williston Park, N.Y.) 2013, 27: 374-81. PMID: 25184258, PMCID: PMC6092183.
  • Advances in therapy for melanoma brain metastases.Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM. Advances in therapy for melanoma brain metastases. Clinics In Dermatology 2013, 31: 264-81. PMID: 23608446, DOI: 10.1016/j.clindermatol.2012.08.008.
  • Studies of NVP-BEZ235 in melanoma.Sznol JA, Jilaveanu LB, Kluger HM. Studies of NVP-BEZ235 in melanoma. Current Cancer Drug Targets 2013, 13: 165-74. PMID: 23215722, DOI: 10.2174/1568009611313020006.
  • Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology 2013, 13: 3. PMID: 23374878, PMCID: PMC3575219, DOI: 10.1186/1472-6890-13-3.
  • c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 343-349. PMID: 23022995, PMCID: PMC3551486, DOI: 10.1093/annonc/mds463.
  • c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2013, 24: 343-349. PMID: 32018405, DOI: 10.1093/annonc/mds463.
  • MEK targeting in N-RAS mutated metastatic melanoma.Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Molecular Cancer 2014, 13: 45. PMID: 24588908, PMCID: PMC3945937, DOI: 10.1186/1476-4598-13-45.
  • Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 3659-66. PMID: 25267741, PMCID: PMC4879709, DOI: 10.1200/JCO.2013.54.8115.
  • Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM. Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International 2014, 14: 4. PMID: 24423208, PMCID: PMC3896780, DOI: 10.1186/1475-2867-14-4.
  • Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: the Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008.Lott JP, Wititsuwannakul J, Lee JJ, Ariyan S, Narayan D, Kluger HH, Lazova R. Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: the Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008. Journal Of The American Academy Of Dermatology 2014, 71: 1077-82. PMID: 25308882, PMCID: PMC6133655, DOI: 10.1016/j.jaad.2014.08.026.
  • NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.Giesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM. NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. Oncotarget 2014, 5: 5209-17. PMID: 24970819, PMCID: PMC4170640, DOI: 10.18632/oncotarget.2101.
  • Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.Scortegagna M, Ruller C, Feng Y, Lazova R, Kluger H, Li JL, De SK, Rickert R, Pellecchia M, Bosenberg M, Ronai ZA. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene 2014, 33: 4330-9. PMID: 24037523, PMCID: PMC3955742, DOI: 10.1038/onc.2013.383.
  • Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Science Translational Medicine 2014, 6: 232ra51. PMID: 24739759, PMCID: PMC6151129, DOI: 10.1126/scitranslmed.3008068.
  • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2014, 32: 1020-30. PMID: 24590637, PMCID: PMC4811023, DOI: 10.1200/JCO.2013.53.0105.
  • PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. Journal Of Cancer 2014, 5: 166-72. PMID: 24563671, PMCID: PMC3931264, DOI: 10.7150/jca.8167.
  • Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20: 3328-37. PMID: 24714776, PMCID: PMC4058354, DOI: 10.1158/1078-0432.CCR-14-0093.
  • Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan S, Narayan D, Sznol M, Kluger HM, Mane S, Schlessinger J, Lifton RP, Halaban R. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nature Genetics 2015, 47: 996-1002. PMID: 26214590, PMCID: PMC4916843, DOI: 10.1038/ng.3361.
  • PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM. PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2015, 21: 2138-47. PMID: 25316811, PMCID: PMC4397107, DOI: 10.1158/1078-0432.CCR-14-0861.
  • Clinical trials in melanoma patients with brain metastases.Yushak ML, Chiang VL, Kluger HM. Clinical trials in melanoma patients with brain metastases. Pigment Cell & Melanoma Research 2015, 28: 741-3. PMID: 26205399, PMCID: PMC4834841, DOI: 10.1111/pcmr.12401.
  • MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.Shuch B, Falbo R, Parisi F, Adeniran A, Kluger Y, Kluger HM, Jilaveanu LB. MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors. BioMed Research International 2015, 2015: 192406. PMID: 26448928, PMCID: PMC4584049, DOI: 10.1155/2015/192406.
  • PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B. PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma? Journal Of Clinical Pathology 2015, 68: 12-7. PMID: 25315900, PMCID: PMC4429054, DOI: 10.1136/jclinpath-2014-202259.
  • Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA, Atkins MB. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2015, 33: 2013-20. PMID: 25800770, PMCID: PMC4517051, DOI: 10.1200/JCO.2014.58.1041.
  • At the front line of combating cancer: an interview with Harriet Kluger, MD.Kluger H, Liu X. At the front line of combating cancer: an interview with Harriet Kluger, MD. The Yale Journal Of Biology And Medicine 2015, 88: 187-9. PMID: 26029017, PMCID: PMC4445440.
  • Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis.Ma B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Research 2015, 75: 487-96. PMID: 25511377, PMCID: PMC4321965, DOI: 10.1158/0008-5472.CAN-13-3339.
  • Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors.Goglia AG, Delsite R, Luz AN, Shahbazian D, Salem AF, Sundaram RK, Chiaravalli J, Hendrikx PJ, Wilshire JA, Jasin M, Kluger HM, Glickman JF, Powell SN, Bindra RS. Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors. Molecular Cancer Therapeutics 2015, 14: 326-42. PMID: 25512618, PMCID: PMC4326563, DOI: 10.1158/1535-7163.MCT-14-0765.
  • Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. Journal Of Immunology (Baltimore, Md. : 1950) 2015, 194: 950-9. PMID: 25539810, PMCID: PMC4380504, DOI: 10.4049/jimmunol.1401686.
  • Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2015, 21: 3052-60. PMID: 25788491, PMCID: PMC4490112, DOI: 10.1158/1078-0432.CCR-14-3073.
  • The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation.Lau E, Feng Y, Claps G, Fukuda MN, Perlina A, Donn D, Jilaveanu L, Kluger H, Freeze HH, Ronai ZA. The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. Science Signaling 2015, 8: ra124. PMID: 26645581, PMCID: PMC4818095, DOI: 10.1126/scisignal.aac6479.
  • Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015, 38: e55-7. PMID: 25805871, PMCID: PMC4370325, DOI: 10.2337/dc14-2349.
  • Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping.Alomari AK, Nettey OS, Singh D, Kluger H, Adeniran AJ. Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping. Human Pathology 2015, 46: 1418-26. PMID: 26239624, DOI: 10.1016/j.humpath.2015.06.006.
  • Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015, 6: 24990-5002. PMID: 26317902, PMCID: PMC4694809, DOI: 10.18632/oncotarget.4572.
  • Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib.Lilly E, Burke M, Kluger H, Choi J. Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib. JAMA Dermatology 2015, 151: 102-3. PMID: 25250477, DOI: 10.1001/jamadermatol.2014.2455.
  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen L, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 5461-5471. PMID: 27169994, PMCID: PMC5106340, DOI: 10.1158/1078-0432.CCR-15-2839.
  • The Treatment of Melanoma Brain Metastases.Kibbi N, Kluger H. The Treatment of Melanoma Brain Metastases. Current Oncology Reports 2016, 18: 73. PMID: 27822695, DOI: 10.1007/s11912-016-0555-4.
  • MET Inhibition in Clear Cell Renal Cell Carcinoma.Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B. MET Inhibition in Clear Cell Renal Cell Carcinoma. Journal Of Cancer 2016, 7: 1205-14. PMID: 27390595, PMCID: PMC4934028, DOI: 10.7150/jca.14604.
  • Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? Journal Of Neurosurgery 2016, 125: 17-23. PMID: 26544782, DOI: 10.3171/2015.6.JNS142763.
  • Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases.Alomari AK, Cohen J, Vortmeyer AO, Chiang A, Gettinger S, Goldberg S, Kluger HM, Chiang VL. Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. Cancer Immunology Research 2016, 4: 481-7. PMID: 26994250, DOI: 10.1158/2326-6066.CIR-15-0238.
  • Melanoma: Clinical Presentations.Kibbi N, Kluger H, Choi JN. Melanoma: Clinical Presentations. Cancer Treatment And Research 2016, 167: 107-29. PMID: 26601860, DOI: 10.1007/978-3-319-22539-5_4.
  • Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. Cancer Chemotherapy And Pharmacology 2016, 77: 1193-200. PMID: 27103123, DOI: 10.1007/s00280-016-3033-7.
  • Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2170-5. PMID: 26864202, PMCID: PMC4776463, DOI: 10.1073/pnas.1525735113.
  • Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2016, 22: 374-82. PMID: 26307133, PMCID: PMC4821426, DOI: 10.1158/1078-0432.CCR-15-1162.
  • Systemic Immunotherapy for the Treatment of Brain Metastases.Cohen JV, Kluger HM. Systemic Immunotherapy for the Treatment of Brain Metastases. Frontiers In Oncology 2016, 6: 49. PMID: 27014624, PMCID: PMC4783384, DOI: 10.3389/fonc.2016.00049.
  • First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, Cohen LJ. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemotherapy And Pharmacology 2016, 77: 155-62. PMID: 26576779, DOI: 10.1007/s00280-015-2909-2.
  • Evolving Immunotherapy Approaches for Renal Cell Carcinoma.Curtis SA, Cohen JV, Kluger HM. Evolving Immunotherapy Approaches for Renal Cell Carcinoma. Current Oncology Reports 2016, 18: 57. PMID: 27475806, DOI: 10.1007/s11912-016-0542-9.
  • Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.Boddupalli CS, Bar N, Kadaveru K, Krauthammer M, Pornputtapong N, Mai Z, Ariyan S, Narayan D, Kluger H, Deng Y, Verma R, Das R, Bacchiocchi A, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight 2016, 1: e88955. PMID: 28018970, PMCID: PMC5161225, DOI: 10.1172/jci.insight.88955.
  • Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.Rutter CE, Johung KL, Yao X, Lu AY, Jilaveanu LB, Yu JB, Contessa JN, Kluger HM, Chiang VLS, Bindra RS. Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. Journal Of Radiosurgery And SBRT 2016, 4: 97-106. PMID: 29296434, PMCID: PMC5658871.
  • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal Of Immunotherapy (Hagerstown, Md. : 1997) 2017, 40: 334-340. PMID: 29028788, PMCID: PMC5647109, DOI: 10.1097/CJI.0000000000000186.
  • Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.Smithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL. Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. Journal For Immunotherapy Of Cancer 2017, 5: 25. PMID: 28331615, PMCID: PMC5359951, DOI: 10.1186/s40425-017-0229-2.
  • From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.Weiss SA, Kluger HM. From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma. Cancer Journal (Sudbury, Mass.) 2017, 23: 1-2. PMID: 28114248, PMCID: PMC5526070, DOI: 10.1097/PPO.0000000000000244.
  • Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.Reddy SB, Possick JD, Kluger HM, Galan A, Han D. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. Journal Of Immunotherapy (Hagerstown, Md. : 1997) 2017, 40: 307-311. PMID: 28737620, DOI: 10.1097/CJI.0000000000000181.
  • Comparing available criteria for measuring brain metastasis response to immunotherapy.Qian JM, Mahajan A, Yu JB, Tsiouris AJ, Goldberg SB, Kluger HM, Chiang VL. Comparing available criteria for measuring brain metastasis response to immunotherapy. Journal Of Neuro-oncology 2017, 132: 479-485. PMID: 28275886, DOI: 10.1007/s11060-017-2398-8.
  • Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy And Oncology : Journal Of The European Society For Therapeutic Radiology And Oncology 2017, 125: 80-88. PMID: 28916225, DOI: 10.1016/j.radonc.2017.08.009.
  • Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28: 1988-1995. PMID: 28595336, PMCID: PMC5834104, DOI: 10.1093/annonc/mdx190.
  • Proteomic and T cell biomarkers identify sensitivity and resistance to immunotherapy in cancer patients.Weber JS, Woods D, Laino A, Kluger H, Halaban R, Sznol M, Roder H, Roder J, Blackmon K, Sullivan R. Proteomic and T cell biomarkers identify sensitivity and resistance to immunotherapy in cancer patients. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28 Suppl 9: ix21. PMID: 32120553, DOI: 10.1093/annonc/mdx553.001.
  • Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 391-398. PMID: 29040030, PMCID: PMC5946731, DOI: 10.1200/JCO.2017.72.2850.
  • A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research 2018, 6: 79-86. PMID: 29208646, DOI: 10.1158/2326-6066.CIR-17-0412.
  • SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.Tamiya H, Kim H, Klymenko O, Kim H, Feng Y, Zhang T, Han JY, Murao A, Snipas SJ, Jilaveanu L, Brown K, Kluger H, Zhang H, Iwai K, Ronai ZA. SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth. The Journal Of Clinical Investigation 2018, 128: 517-530. PMID: 29227283, PMCID: PMC5749505, DOI: 10.1172/JCI95410.
  • Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.Jilaveanu LB, Puligandla M, Weiss SA, Wang VX, Zito CR, Flaherty KT, Boeke M, Neumeister VM, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas N, Kluger HM. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 217-223. PMID: 29066509, PMCID: PMC5904512, DOI: 10.1158/1078-0432.CCR-17-1555.
  • Early B cell changes predict autoimmunity following combination immune checkpoint blockade.Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. The Journal Of Clinical Investigation 2018, 128: 715-720. PMID: 29309048, PMCID: PMC5785243, DOI: 10.1172/JCI96798.
  • Genomic Heterogeneity and the Small Renal Mass.Ueno D, Xie Z, Boeke M, Syed J, Nguyen KA, McGillivray P, Adeniran A, Humphrey PA, Dancik GM, Kluger Y, Liu Z, Kluger HM, Shuch B. Genomic Heterogeneity and the Small Renal Mass. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2018, 24: 4137-4144. PMID: 29760223, PMCID: PMC6125159, DOI: 10.1158/1078-0432.CCR-18-0214.
  • Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 2018, 67: 1471-1480. PMID: 29937434, PMCID: PMC6054443, DOI: 10.2337/dbi18-0002.
  • Anti-PD-1 Therapy-Associated Perforating Colitis.Celli R, Kluger HM, Zhang X. Anti-PD-1 Therapy-Associated Perforating Colitis. Case Reports In Gastrointestinal Medicine 2018, 2018: 3406437. PMID: 29955400, PMCID: PMC6000840, DOI: 10.1155/2018/3406437.
  • Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren N, Shinohara MM, Kluger HM, Bhatia S, Lundgren L, Cheever MA, Topalian SL, Nghiem P. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. Journal For Immunotherapy Of Cancer 2018, 6: 131. PMID: 30482247, PMCID: PMC6258401, DOI: 10.1186/s40425-018-0450-7.
  • Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 52-60. PMID: 30407895, PMCID: PMC6354772, DOI: 10.1200/JCO.18.00204.
  • Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2019, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.
  • Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KR, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 2442-2449. PMID: 30617133, PMCID: PMC6467753, DOI: 10.1158/1078-0432.CCR-18-2652.
  • Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.Hellerstedt BA, Vogelzang NJ, Kluger HM, Yasenchak CA, Aftab DT, Ramies DA, Gordon MS, Lara P. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma. Clinical Lung Cancer 2019, 20: 74-81.e1. PMID: 30528315, DOI: 10.1016/j.cllc.2018.10.006.
  • Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.Kim JM, Materin MA, Sznol M, Kluger H, Weiss S, Chow J, Stoessel K, Kombo N, Del Priore L, Pointdujour-Lim R. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. Ophthalmology 2019, 126: 1058-1062. PMID: 30735682, PMCID: PMC6933747, DOI: 10.1016/j.ophtha.2019.01.031.
  • Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell & Melanoma Research 2019, 32: 458-469. PMID: 30712316, PMCID: PMC7771318, DOI: 10.1111/pcmr.12771.
  • Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 693-702. PMID: 30726175, PMCID: PMC6424137, DOI: 10.1200/JCO.18.01896.
  • Reply to A. Shinde et al.Kluger HM, Margolin KA, Davies MA, Long GV, Tawbi HA, Goldberg SB, Chiang VL. Reply to A. Shinde et al. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 1031-1032. PMID: 30807233, DOI: 10.1200/JCO.18.02463.
  • Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.Wingrove E, Liu ZZ, Patel KD, Arnal-Estapé A, Cai WL, Melnick MA, Politi K, Monteiro C, Zhu L, Valiente M, Kluger HM, Chiang VL, Nguyen DX. Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. Cell Reports 2019, 27: 1277-1292.e7. PMID: 31018140, PMCID: PMC6592283, DOI: 10.1016/j.celrep.2019.03.085.
  • A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discovery 2019, 9: 711-721. PMID: 30988166, DOI: 10.1158/2159-8290.CD-18-1495.
  • High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 5503-5512. PMID: 31189645, PMCID: PMC6744974, DOI: 10.1158/1078-0432.CCR-19-0104.
  • B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For Immunotherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.
  • Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. Journal For Immunotherapy Of Cancer 2019, 7: 194. PMID: 31337426, PMCID: PMC6651990, DOI: 10.1186/s40425-019-0675-0.
  • Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For Immunotherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.
  • Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy.Tran TT, Mahajan A, Chiang VL, Goldberg SB, Nguyen DX, Jilaveanu LB, Kluger HM. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy. Journal For Immunotherapy Of Cancer 2019, 7: 200. PMID: 31362777, PMCID: PMC6668163, DOI: 10.1186/s40425-019-0684-z.
  • Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors.Qian JM, Yu JB, Mahajan A, Goldberg SB, Kluger HM, Chiang VLS. Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors. International Journal Of Radiation Oncology, Biology, Physics 2019, 105: 1113-1118. PMID: 31479702, DOI: 10.1016/j.ijrobp.2019.08.053.
  • Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.Hamid O, Molinero L, Bolen CR, Sosman JA, Muñoz-Couselo E, Kluger HM, McDermott DF, Powderly J, Sarkar I, Ballinger M, Fassò M, O'Hear C, Chen DS, Hegde PS, Hodi FS. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 6061-6072. PMID: 31358540, DOI: 10.1158/1078-0432.CCR-18-3488.
  • Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study.Suarez-Sarmiento A, Nguyen KA, Syed JS, Nolte A, Ghabili K, Cheng M, Liu S, Chiang V, Kluger H, Hurwitz M, Shuch B. Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study. Clinical Genitourinary Cancer 2019, 17: e1163-e1170. PMID: 31519468, DOI: 10.1016/j.clgc.2019.08.006.
  • Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2019, 37: 3350-3358. PMID: 31498030, PMCID: PMC6901280, DOI: 10.1200/JCO.19.00345.
  • Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.Gupta S, McCann L, Chan YGY, Lai EW, Wei W, Wong PF, Smithy JW, Weidler J, Rhees B, Bates M, Kluger HM, Rimm DL. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. Journal For Immunotherapy Of Cancer 2019, 7: 254. PMID: 31533832, PMCID: PMC6751819, DOI: 10.1186/s40425-019-0731-9.
  • Complications associated with immunotherapy for brain metastases.Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/WCO.0000000000000756.
  • Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death.Kulkarni PM, Robinson EJ, Sarin Pradhan J, Gartrell-Corrado RD, Rohr BR, Trager MH, Geskin LJ, Kluger HM, Wong PF, Acs B, Rizk EM, Yang C, Mondal M, Moore MR, Osman I, Phelps R, Horst BA, Chen ZS, Ferringer T, Rimm DL, Wang J, Saenger YM. Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 1126-1134. PMID: 31636101, PMCID: PMC8142811, DOI: 10.1158/1078-0432.CCR-19-1495.
  • Histopathology-guided mass spectrometry differentiates benign nevi from malignant melanoma.Lazova R, Smoot K, Anderson H, Powell MJ, Rosenberg AS, Rongioletti F, Pilloni L, D'Hallewin S, Gueorguieva R, Tantcheva-Poór I, Obadofin O, Camacho C, Hsi A, Kluger HH, Fadare O, Seeley EH. Histopathology-guided mass spectrometry differentiates benign nevi from malignant melanoma. Journal Of Cutaneous Pathology 2020, 47: 226-240. PMID: 31697431, DOI: 10.1111/cup.13610.
  • PLEKHA5 regulates tumor growth in metastatic melanoma.Zhang H, Zhu H, Deng G, Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg MW, Kluger HM, Jilaveanu LB. PLEKHA5 regulates tumor growth in metastatic melanoma. Cancer 2020, 126: 1016-1030. PMID: 31769872, PMCID: PMC7147081, DOI: 10.1002/cncr.32611.
  • Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions.Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon I, Liu JKC, Ahmed KA, Arrington JA, Evernden BR, Smalley I, Eroglu Z, Khushalani N, Margolin K, Kluger H, Atkins MB, Tawbi H, Boire A, Forsyth P. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell & Melanoma Research 2020, 33: 527-541. PMID: 31916400, DOI: 10.1111/pcmr.12861.
  • High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis.Yang C, Shuch B, Kluger H, Humphrey PA, Adeniran AJ. High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis. The American Journal Of Surgical Pathology 2020, 44: 582-593. PMID: 32101890, DOI: 10.1097/PAS.0000000000001455.
  • Identification of Two Forms of Human Plasma Renalase, and Their Association With All-Cause Mortality.Chang J, Guo X, Rao V, Gromisch ES, Chung S, Kluger HM, Cha C, Gorelick F, Testani J, Safirstein R, Crowley S, Peixoto AJ, Desir GV. Identification of Two Forms of Human Plasma Renalase, and Their Association With All-Cause Mortality. Kidney International Reports 2020, 5: 362-368. PMID: 32154458, PMCID: PMC7056858, DOI: 10.1016/j.ekir.2019.12.002.
  • Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.Klemen ND, Wang M, Rubinstein JC, Olino K, Clune J, Ariyan S, Cha C, Weiss SA, Kluger HM, Sznol M. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. Journal For Immunotherapy Of Cancer 2020, 8 PMID: 32209601, PMCID: PMC7103823, DOI: 10.1136/jitc-2019-000341.
  • Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. Journal For Immunotherapy Of Cancer 2020, 8 PMID: 32238470, PMCID: PMC7174063, DOI: 10.1136/jitc-2019-000398.
  • Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet. Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/S1470-2045(20)30111-X.
  • PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice.Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2020, 26: 4186-4197. PMID: 32354698, DOI: 10.1158/1078-0432.CCR-20-0798.
  • Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance.Avitan-Hersh E, Feng Y, Vaisman AO, Ahmed YA, Zohar Y, Zhang T, Lee JS, Lazar I, Khalil SS, Feiler Y, Kluger H, Kahana C, Brown K, Ruppin E, Ronai ZA, Orian A. Regulation of eIF2α by RNF4 Promotes Melanoma Tumorigenesis and Therapy Resistance. The Journal Of Investigative Dermatology 2020, 140: 2466-2477. PMID: 32360601, PMCID: PMC8081033, DOI: 10.1016/j.jid.2020.04.008.
  • Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discovery 2020, 10: 1158-1173. PMID: 32439653, DOI: 10.1158/2159-8290.CD-19-1510.
  • Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series.Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.
  • Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic.Kluger DM, Aizenbud Y, Jaffe A, Parisi F, Aizenbud L, Minsky-Fenick E, Kluger JM, Farhadian S, Kluger HM, Kluger Y. Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic. Infection Control And Hospital Epidemiology 2020, 41: 1443-1445. PMID: 32684183, PMCID: PMC7403749, DOI: 10.1017/ice.2020.337.
  • Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.Weiss SA, Zito C, Tran T, Heishima K, Neumeister V, McGuire J, Adeniran A, Kluger H, Jilaveanu LB. Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. Journal Of Neuro-oncology 2021, 152: 15-25. PMID: 32974852, PMCID: PMC7910371, DOI: 10.1007/s11060-020-03619-0.
  • Targeting Innate Immunity to Treat Cancer.Austin M, Kluger H. Targeting Innate Immunity to Treat Cancer. Cancers 2020, 12 PMID: 32977403, PMCID: PMC7597964, DOI: 10.3390/cancers12102723.
  • Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck.Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology--head And Neck Surgery : Official Journal Of American Academy Of Otolaryngology-Head And Neck Surgery 2021, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.
  • [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis.Tran TT, Gallezot JD, Jilaveanu LB, Zito C, Turcu G, Lim K, Nabulsi N, Huang H, Huttner A, Kluger HM, Chiang VL, Carson R. [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Molecular Imaging 2020, 19: 1536012120968669. PMID: 33147119, PMCID: PMC7649862, DOI: 10.1177/1536012120968669.
  • Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States.Jacobs D, Huang H, Olino K, Weiss S, Kluger H, Judson BL, Zhang Y. Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States. JAMA Dermatology 2021, 157: 59-65. PMID: 33146688, PMCID: PMC7643047, DOI: 10.1001/jamadermatol.2020.4102.
  • Cardiac Biventricular Metastasis From Renal Cell Carcinoma.Latifi AN, Ibe U, Arbune A, Kluger H, Baldassarre LA. Cardiac Biventricular Metastasis From Renal Cell Carcinoma. Cure¯us 2020, 12: e10870. PMID: 33178523, PMCID: PMC7652367, DOI: 10.7759/cureus.10870.
  • Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology 2020, 10: 1864909. PMID: 33457084, PMCID: PMC7781756, DOI: 10.1080/2162402X.2020.1864909.
  • Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.Martinez-Morilla S, Villarroel-Espindola F, Wong PF, Toki MI, Aung TN, Pelekanou V, Bourke-Martin B, Schalper KA, Kluger HM, Rimm DL. Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 1987-1996. PMID: 33504554, PMCID: PMC8026677, DOI: 10.1158/1078-0432.CCR-20-3340.
  • Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma.Moore MR, Friesner ID, Rizk EM, Fullerton BT, Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Geskin LJ, Horst B, Gardner K, Niedt G, Celebi JT, Gartrell-Corrado RD, Messina J, Ferringer T, Rimm DL, Saltz J, Wang J, Vanguri R, Saenger YM. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. Scientific Reports 2021, 11: 2809. PMID: 33531581, PMCID: PMC7854647, DOI: 10.1038/s41598-021-82305-1.
  • Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity.Higgins AY, Arbune A, Soufer A, Ragheb E, Kwan JM, Lamy J, Henry M, Cuomo JR, Charifa A, Gallegos C, Hull S, Coviello JS, Bader AS, Peters DC, Huber S, Mojibian HR, Sinusas AJ, Kluger H, Baldassarre LA. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PloS One 2021, 16: e0246764. PMID: 33606757, PMCID: PMC7895343, DOI: 10.1371/journal.pone.0246764.
  • Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells.Lucca LE, Axisa PP, Lu B, Harnett B, Jessel S, Zhang L, Raddassi K, Zhang L, Olino K, Clune J, Singer M, Kluger HM, Hafler DA. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. The Journal Of Experimental Medicine 2021, 218 PMID: 33651881, PMCID: PMC7933991, DOI: 10.1084/jem.20200921.
  • Adverse events induced by immune checkpoint inhibitors.Perdigoto AL, Kluger H, Herold KC. Adverse events induced by immune checkpoint inhibitors. Current Opinion In Immunology 2021, 69: 29-38. PMID: 33640598, PMCID: PMC8122053, DOI: 10.1016/j.coi.2021.02.002.
  • Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report.Jessel S, Austin M, Kluger HM. Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. Clinical Oncology, Case Reports 2021, 4 PMID: 33763663, PMCID: PMC7985664.
  • Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.Perdigoto AL, Tran T, Patel N, Clark P, Patell K, Stamatouli AM, Reddy V, Clune J, Herold KC, Robert ME, Kluger HM. Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. Clinical Oncology, Case Reports 2020, 3 PMID: 33778814, PMCID: PMC7993656.
  • Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells.Tran TT, Rane CK, Zito CR, Weiss SA, Jessel S, Lucca L, Lu BY, Oria VO, Adeniran A, Chiang VL, Omay SB, Hafler DA, Kluger HM, Jilaveanu LB. Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. Cancers 2021, 13 PMID: 33801444, PMCID: PMC7958624, DOI: 10.3390/cancers13051049.
  • Agonistic CD40 Antibodies in Cancer Treatment.Djureinovic D, Wang M, Kluger HM. Agonistic CD40 Antibodies in Cancer Treatment. Cancers 2021, 13 PMID: 33804039, PMCID: PMC8000216, DOI: 10.3390/cancers13061302.
  • Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Journal For Immunotherapy Of Cancer 2021, 9 PMID: 33879601, PMCID: PMC8061836, DOI: 10.1136/jitc-2021-002478.
  • Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma.Zhu G, Su H, Johnson CH, Khan SA, Kluger H, Lu L. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. European Journal Of Cancer (Oxford, England : 1990) 2021, 151: 25-34. PMID: 33962358, PMCID: PMC8184628, DOI: 10.1016/j.ejca.2021.03.053.
  • Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality.Vathiotis IA, Yang Z, Reeves J, Toki M, Aung TN, Wong PF, Kluger H, Syrigos KN, Warren S, Rimm DL. Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. NPJ Precision Oncology 2021, 5: 45. PMID: 34050252, PMCID: PMC8163775, DOI: 10.1038/s41698-021-00184-1.
  • Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. Journal For Immunotherapy Of Cancer 2021, 9 PMID: 33963015, PMCID: PMC8108687, DOI: 10.1136/jitc-2021-002535.
  • Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2021, 39: 2656-2666. PMID: 33979178, PMCID: PMC8376325, DOI: 10.1200/JCO.21.00612.
  • Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.Berry S, Giraldo NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, Jessel S, Doyle J, Signer D, Wilton R, Roskes JS, Eminizer M, Park S, Sunshine JC, Jaffee EM, Baras A, De Marzo AM, Topalian SL, Kluger H, Cope L, Lipson EJ, Danilova L, Anders RA, Rimm DL, Pardoll DM, Szalay AS, Taube JM. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science (New York, N.Y.) 2021, 372 PMID: 34112666, PMCID: PMC8709533, DOI: 10.1126/science.aba2609.
  • A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 4757-4767. PMID: 34140403, DOI: 10.1158/1078-0432.CCR-21-0903.
  • Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF.Cheok SK, Narayan A, Arnal-Estape A, Gettinger S, Goldberg SB, Kluger HM, Nguyen D, Patel A, Chiang V. Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF. JCO Precision Oncology 2021, 5 PMID: 34250381, PMCID: PMC8232069, DOI: 10.1200/PO.20.00292.
  • Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal Of Neuro-oncology 2021, 154: 197-203. PMID: 34351544, DOI: 10.1007/s11060-021-03813-8.
  • Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.Unlu S, Grant MJ, Gettinger S, Adeniran A, Kluger HM. Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. Clinical Oncology, Case Reports 2021, 4 PMID: 34382032, PMCID: PMC8353529.
  • Correction to: Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis.Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss SA, Goldberg SB, Aboian MS, Kluger HM, Mahajan A. Correction to: Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal Of Neuro-oncology 2021, 154: 205. PMID: 34403041, DOI: 10.1007/s11060-021-03825-4.
  • Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis.Yang C, Shuch B, Kluger HM, Serrano M, Kibel AS, Humphrey PA, Adeniran AJ. Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. American Journal Of Clinical Pathology 2021, 156: 550-558. PMID: 34424955, DOI: 10.1093/ajcp/aqab015.
  • Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases.Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL. Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. American Journal Of Clinical Oncology 2021, 44: 495-501. PMID: 34432667, DOI: 10.1097/COC.0000000000000849.
  • Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally.Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. Merkel Cell Carcinoma: Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals Of Surgical Oncology 2022, 29: 415-424. PMID: 34494169, PMCID: PMC8677689, DOI: 10.1245/s10434-021-10727-2.
  • ASO Visual Abstract: Merkel Cell Carcinoma-Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally.Esposito A, Jacobs D, Ariyan S, Galan A, Kluger H, Clune J, Weiss S, Tran T, Olino K. ASO Visual Abstract: Merkel Cell Carcinoma-Changing Practice Patterns and Impact on Recurrence-Free and Overall Survival at a Single Institution and Nationally. Annals Of Surgical Oncology 2021, 28: 736-737. PMID: 34564774, DOI: 10.1245/s10434-021-10784-7.
  • Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases.Lu BY, Gupta R, Aguirre-Ducler A, Gianino N, Wyatt H, Ribeiro M, Chiang VL, Contessa JN, Adeniran AJ, Jilaveanu LB, Kluger HM, Schalper KA, Goldberg SB. Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases. Journal For Immunotherapy Of Cancer 2021, 9 PMID: 34670827, PMCID: PMC8529973, DOI: 10.1136/jitc-2021-002684.
  • KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements.Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature 2021, 598: 682-687. PMID: 34671158, PMCID: PMC8555464, DOI: 10.1038/s41586-021-03994-2.
  • Central Nervous System Metastases.Nieblas-Bedolla E, Zuccato J, Kluger H, Zadeh G, Brastianos PK. Central Nervous System Metastases. Hematology/oncology Clinics Of North America 2022, 36: 161-188. PMID: 34711458, DOI: 10.1016/j.hoc.2021.08.004.
  • CheckMate-067: Raising the Bar for the Next Decade in Oncology.Weiss SA, Kluger H. CheckMate-067: Raising the Bar for the Next Decade in Oncology. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, 40: 111-113. PMID: 34855466, PMCID: PMC8718180, DOI: 10.1200/JCO.21.02549.
  • Emerging Studies of Melanoma Brain Metastasis.Caulfield JI, Kluger HM. Emerging Studies of Melanoma Brain Metastasis. Current Oncology Reports 2022, 24: 585-594. PMID: 35212922, DOI: 10.1007/s11912-022-01237-9.
  • TCR-sequencing in cancer and autoimmunity: barcodes and beyond.Pauken KE, Lagattuta KA, Lu BY, Lucca LE, Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH. TCR-sequencing in cancer and autoimmunity: barcodes and beyond. Trends In Immunology 2022, 43: 180-194. PMID: 35090787, PMCID: PMC8882139, DOI: 10.1016/j.it.2022.01.002.
  • Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review.Heng JS, Kim JM, Jones DK, Stoessel KM, Weiss SA, Sznol M, Kluger HM, Walter SD, Silverstein NA, Pointdujour-Lim R. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. BMJ Open Ophthalmology 2022, 7: e000889. PMID: 35047671, PMCID: PMC8724805, DOI: 10.1136/bmjophth-2021-000889.
  • Inhibition of renalase drives tumour rejection by promoting T cell activation.Guo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Inhibition of renalase drives tumour rejection by promoting T cell activation. European Journal Of Cancer (Oxford, England : 1990) 2022, 165: 81-96. PMID: 35219026, PMCID: PMC8940682, DOI: 10.1016/j.ejca.2022.01.002.
  • Reply to T. Olivier et al.Wolchok JD, Kluger H, Campigotto F, Larkin J, Hodi FS. Reply to T. Olivier et al. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, 40: 1597-1598. PMID: 35258992, PMCID: PMC9084429, DOI: 10.1200/JCO.22.00209.
  • Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For Immunotherapy Of Cancer 2022, 10 PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.
  • Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function.Jessel S, Weiss SA, Austin M, Mahajan A, Etts K, Zhang L, Aizenbud L, Perdigoto AL, Hurwitz M, Sznol M, Herold KC, Kluger HM. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Frontiers In Oncology 2022, 12: 836859. PMID: 35350573, PMCID: PMC8958012, DOI: 10.3389/fonc.2022.836859.

Clinical Trials

ConditionsStudy Title
Phase IA Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, PK, PD, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients With Relapsed or Refractory Solid Tumors
Melanoma, skinA Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma
Unknown Sites; Urinary BladderAdvanced Cardiovascular Magnetic Resonance for Detection of Programmed Cell Death Protein-1 Deficient Myocarditis
Edit Profile